

6-17-04


16364
17/04/04

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV457202598US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 16, 2004

Signature:

(Richard Zimmermann)



Docket No.: 28335/36996US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Jeffrey S. Bartlett

Confirmation No.:

Application No.: 10/038,972

Art Unit: 1636

Filed: January 4, 2002

Examiner: M. Marvich

For: AAV2 VECTORS AND METHODS

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The Applicants request that the documents listed on the attached Form PTO-1449 be made of official record in the above-identified application and considered by the Examiner during examination of the above-identified patent application. Copies of all documents (B1 and C1-C21) are submitted herewith.


This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes prior art under 35 U.S.C. §102 or §103.

06/18/2004 JADDO1 00000101 10038972
01 FC:1806 180.00 OP

This Information Disclosure Statement is filed after receipt of a first Office Action on the merits. Submitted herewith is our check (\$180.00) for payment of the fee according to 37 C.F.R. §1.97(b)(3). Please charge any additional fees due in connection with this Information Disclosure Statement to Deposit Account No. 13-2855.

Dated: June 16, 2004

Respectfully submitted,

By: 

Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357


(312) 474-6300

Agent for Applicant

Form PTO-1449 (Modified)

Atty. Docket No.
28335/36996USSerial No.
10/038,972Applicant(s)
Jeffrey S. BartlettFiling Date
January 4, 2003Art Unit
1636**INFORMATION DISCLOSURE STATEMENT**

JUN 17 2004

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation	
				Yes	No
B1	WO00/28004	05/18/2000	PCT		

OTHER DOCUMENTS

C1	Srivastava, <i>et al.</i> , Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome, <i>Journal of Virology</i> 45 (2): 555-564 (February 1983).
C2	Ruffing <i>et al.</i> , Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif, <i>Journal of General Virology</i> 75: 3385-3392 (1994).
C3	Hermonat <i>et al.</i> , Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants, <i>Journal of Virology</i> 51 (2): 329-339 (August 1984).
C4	Santiago <i>et al.</i> , New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury, <i>Nature Medicine</i> 5 (11): 1264-1269 (November 1999).
C5	Muzyczka, Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells, <i>Current Topics in Microbiology and Immunology</i> 158: 97-129 (1992).
C6	Girod <i>et al.</i> , Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2, <i>Nature Medicine</i> 5 (9): 1052-1056 (September 1999).
C7	Rabinowitz <i>et al.</i> , Insertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus, <i>Virology</i> 265: 274-285 (1999).

EXAMINER:

DATE CONSIDERED:

JUN 17 2004

INFORMATION DISCLOSURE STATEMENT

Atty. Docket No. 28335/36996US	Serial No. 10/038,972
Applicant(s) Jeffrey S. Bartlett	
Filing Date January 4, 2003	Art Unit 1636

C8	Tsao <i>et al.</i> , The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications, <i>Science</i> 251: 1456-1464 (March 1991).
C9	Wu <i>et al.</i> , The Canine Parvovirus Empty Capsid Structure, <i>J. Mol. Biol.</i> 233 (2): 231-244 (1993).
C10	Agbandje <i>et al.</i> , Structure Determination of Feline Panleukopenia Virus Empty Particles, <i>Proteins</i> 16: 155-171 (June 1993).
C11	Agbandje-McKenna <i>et al.</i> , Functional implications of the structure of the murine parvovirus, minute virus of mice, <i>Structure</i> 6 (11): 1369-1381 (November 1998).
C12	Llamas-Saiz <i>et al.</i> , Structure Determination of Minute Virus of Mice, <i>Acta Crystallographica Section D</i> D53: 93-102 (1997).
C13	Chipman <i>et al.</i> , Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor, <i>Proc. Natl. Acad. Sci. USA</i> 93: 7502-7506 (July 1996).
C14	McKenna <i>et al.</i> , Three-Dimensional Structure of Aleutian Mink Disease Parvovirus: Implications for Disease Pathogenicity, <i>Journal of Virology</i> 73 (8): 6882-6891 (August 1999).
C15	Wu <i>et al.</i> , Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism, <i>Journal of Virology</i> 74 (18): 8635-8647 (September 2000).
C16	Shi <i>et al.</i> , Insertional Mutagenesis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Generation of AAV2 Vectors Targeted to Alternative Cell-Surface Receptors, <i>Human Gene Therapy</i> , 12: 1697-1711 (September 2001).
C17	Bartlett <i>et al.</i> , Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors. <i>Journal of Virology</i> , 74(6): 2777-2785 (1999).
C18	Kigawa <i>et al.</i> , Adenovirus-mediated Transfer of a p53 Gene in Ovarian Cancer, <i>Adv. Exp. Med. Biol.</i> 465(14): 207-14 (2000).
C19	Song <i>et al.</i> , In vivo Studies of Adenovirus-mediated p53 Gene Therapy for Cis-platinum-Resistant Human Ovarian Tumor Xenografts, <i>Oncol. Res.</i> , 11(3): 153-159m (1999).
C20	Yamaguchi <i>et al.</i> , Co-transfection of Herpes Simplex Virus Thymidine Kinase Gene and Human Interleukin-2 Gene into Mouse Ovarian Cancer Cell Line, OVHM, <i>Intl. J. Mol. Med.</i> , 6(2): 185-190 (2000).
C21	Genbank Accession No. AF043303, Adeno-Associated Virus 2 (February 24, 1998)